相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of BCR::ABL1-Negative Myeloproliferative Neoplasm
Norman Abbou et al.
CELLS (2023)
Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management
Mrinal M. Patnaik et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
Chronic Eosinophilic Leukaemia Associated with JAK2 Exon 13 Insertion/Deletion Mutations
Nicholas Lafferty et al.
ACTA HAEMATOLOGICA (2022)
Cytogenetic abnormalities in essential thrombocythemia: Clinical and molecular correlates and prognostic relevance in 809 informative cases
Naseema Gangat et al.
BLOOD CANCER JOURNAL (2022)
Genetic Background of Polycythemia Vera
Mathilde Regimbeau et al.
GENES (2022)
The Cytogenetic Landscape of Pediatric Chronic Myeloid Leukemia Diagnosed in Chronic Phase
Axel Karow et al.
CANCERS (2022)
Chronic Neutrophilic Leukemia: A Comprehensive Review of Clinical Characteristics, Genetic Landscape and Management
Thomas P. Thomopoulos et al.
FRONTIERS IN ONCOLOGY (2022)
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Daniel A. Arber et al.
BLOOD (2022)
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
Joseph D. Khoury et al.
LEUKEMIA (2022)
Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS)
Guillermo Montalban-Bravo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms
Clemence Marcault et al.
BLOOD (2021)
Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia
Diletta Fontana et al.
FRONTIERS IN ONCOLOGY (2021)
Myeloid/lymphoid neoplasms with FLT3 rearrangement
Guilin Tang et al.
MODERN PATHOLOGY (2021)
Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia
Yotaro Ochi et al.
NATURE COMMUNICATIONS (2021)
A novel activating JAK1 mutation in chronic eosinophilic leukemia
William Shomali et al.
BLOOD ADVANCES (2021)
Precision Medicine in Systemic Mastocytosis
Maura Nicolosi et al.
MEDICINA-LITHUANIA (2021)
Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia
Jean-Michel Cayuela et al.
BULLETIN DU CANCER (2020)
Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients
Abhishek A. Mangaonkar et al.
LEUKEMIA (2020)
Chronic neutrophilic leukemia: 2020 update on diagnosis, molecular genetics, prognosis, and management
Natasha Szuber et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera
Ayalew Tefferi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
PTPN11 mutation with additional somatic alteration indicates unfavorable outcome in juvenile myelomonocytic leukemia: a retrospective clinical study from a single center
Yan Miao et al.
EUROPEAN JOURNAL OF PEDIATRICS (2020)
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2020)
WHO defined chronic eosinophilic leukemia, not otherwise specified (CEL, NOS): A contemporary series from the Mayo Clinic
Erika Morsia et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes
Juliana Schwaab et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
High-risk additional chromosomal abnormalities at low blast counts herald death by CML
Ruediger Hehlmann et al.
LEUKEMIA (2020)
A population-based study of chronic eosinophilic leukemia-not otherwise specified in the United States
Gordon J. Ruan et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Epidemiology, clinical picture and long-term outcomes ofFIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia: Data from 151 patients
Julien Rohmer et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Atypical Chronic Myeloid Leukemia: Where Are We Now?
Elena Crisa et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes
Mrinal M. Patnaik et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2020)
The New ELN Recommendations for Treating CML
Rudiger Hehlmann
JOURNAL OF CLINICAL MEDICINE (2020)
Juvenile myelomonocytic leukemia: who's the driver at the wheel?
Charlotte M. Niemeyer et al.
BLOOD (2019)
Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia
Susan Branford et al.
LEUKEMIA (2019)
Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children's Oncology Group CML Working Group
Uma Athale et al.
PEDIATRIC BLOOD & CANCER (2019)
JAK2ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera
Ami B. Patel et al.
BLOOD (2019)
High-Risk Additional Chromosomal Abnormalities in CML Herald Death By Blast Crisis Already at Low Blast Levels
Rudiger Hehlmann et al.
BLOOD (2019)
Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia
Audrey Bidet et al.
HAEMATOLOGICA (2019)
Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia
Nicholas C. P. Cross et al.
LEUKEMIA (2019)
Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study
Guilin Tang et al.
MODERN PATHOLOGY (2019)
Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor
S. Verstovsek et al.
ANNALS OF ONCOLOGY (2018)
Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis
Nicole Naumann et al.
GENES CHROMOSOMES & CANCER (2018)
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project
Barbara Mora et al.
HAEMATOLOGICA (2018)
Validation of the EUTOS long-term survival score in a recent independent cohort of real world CML patients
Inge G. P. Geelen et al.
LEUKEMIA (2018)
GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis
Ayalew Tefferi et al.
LEUKEMIA (2018)
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
Tiziano Barbuil et al.
LEUKEMIA (2018)
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project
Barbara Mora et al.
HAEMATOLOGICA (2018)
Cytogenetic abnormalities in systemic mastocytosis: WHO subcategory-specific incidence and prognostic impact among 348 informative cases
Sahrish Shah et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable
Prithviraj Bose et al.
BLOOD (2018)
Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models
Animesh Pardanani et al.
BLOOD ADVANCES (2018)
Molecular monitoring of patients with ETV6-PDGFRB rearrangement: Implications for therapeutic adaptation
Audrey Bidet et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Cytogenetic findings in WHO-defined polycythaemia vera and their prognostic relevance
Daniela Barraco et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera
Guilin Tang et al.
HAEMATOLOGICA (2017)
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Andreas Hochhaus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia
E. Togasaki et al.
BLOOD CANCER JOURNAL (2017)
Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera
Guilin Tang et al.
HAEMATOLOGICA (2017)
Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy
Zimu Gong et al.
BLOOD ADVANCES (2017)
Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management
Mrinal M. Patnaik et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing
Mrinal M. Patnaik et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy
Wei Wang et al.
BLOOD (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK's population-based Haematological Malignancy Research Network 2004-15
Eve Roman et al.
CANCER EPIDEMIOLOGY (2016)
Characterization of leukemias with ETV6-ABL1 fusion
Marketa Zaliova et al.
HAEMATOLOGICA (2016)
Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified
Sa A. Wang et al.
MODERN PATHOLOGY (2016)
Diagnosis and treatment of juvenile myelomonocytic leukemia
Kazuo Sakashita et al.
PEDIATRICS INTERNATIONAL (2016)
Characterization of leukemias with ETV6-ABL1 fusion
Marketa Zaliova et al.
HAEMATOLOGICA (2016)
Targeted deep sequencing in primary myelofibrosis
Ayalew Tefferi et al.
BLOOD ADVANCES (2016)
Targeted deep sequencing in polycythemia vera and essential thrombocythemia
Ayalew Tefferi et al.
BLOOD ADVANCES (2016)
Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML
Alice Fabarius et al.
ANNALS OF HEMATOLOGY (2015)
3q26/EVI1 rearrangements in myeloid hemopathies: a cytogenetic review
Marc De Braekeleer et al.
FUTURE ONCOLOGY (2015)
The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries
V. S. Hoffmann et al.
LEUKEMIA (2015)
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV
L. Kalmanti et al.
LEUKEMIA (2015)
Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors
S. Cerquozzi et al.
BLOOD CANCER JOURNAL (2015)
A compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients
Emnet Wassie et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Transplantation for juvenile myelomonocytic leukemia: a retrospective study of 30 children treated with a regimen of busulfan, fludarabine, and melphalan
Miharu Yabe et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2015)
Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution
Guilin Tang et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study
Emnet A. Wassie et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms
Sa A. Wang et al.
BLOOD (2014)
Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities?
Barbara J. Bain et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union
Odile Moulard et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2014)
Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase
Michael Lauseker et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2014)
Clonal chromosomal abnormalities in Philadelphia-negative cells in chronic myeloid leukemia patients treated with nilotinib used in first-line therapy
Huafeng Wang et al.
ANNALS OF HEMATOLOGY (2013)
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani et al.
BLOOD (2013)
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
A. Tefferi et al.
LEUKEMIA (2013)
SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations
M. Meggendorfer et al.
LEUKEMIA (2013)
Oncogenic CSF3R Mutations in Chronic Neutrophilic Leukemia and Atypical CML
Julia E. Maxson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Chronic eosinophilic leukemia-not otherwise specified has a poor prognosis with unresponsiveness to conventional treatment and high risk of acute transformation
Grzegorz Helbig et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
The long-term clinical implications of clonal chromosomal abnormalities in newly diagnosed chronic phase chronic myeloid leukemia patients treated with imatinib mesylate
Sung-Eun Lee et al.
CANCER GENETICS (2012)
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV
Alice Fabarius et al.
BLOOD (2011)
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score
Joerg Hasford et al.
BLOOD (2011)
Cytogenetic risk stratification in chronic myelomonocytic leukemia
Esperanza Such et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
Naseema Gangat et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia
C. Roche-Lestienne et al.
LEUKEMIA (2011)
Genomic characterization of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patients
Sami Joha et al.
LEUKEMIA RESEARCH (2011)
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications
Alfonso Zaccaria et al.
CANCER GENETICS AND CYTOGENETICS (2010)
Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis
Johanna Flach et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis
Philipp Erben et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance
Catherine Roche-Lestienne et al.
BLOOD (2008)
Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia
Valeria A. S. De Melo et al.
BLOOD (2007)
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells
Michael W. N. Deininger et al.
CANCER (2007)
Monosomy 7 in t(9;22)-negative cells during nilotinib therapy in an imatinib-resistant chronic myeloid leukemia case
Amer Zeidan et al.
CANCER GENETICS AND CYTOGENETICS (2007)
Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia
Craig Kovitz et al.
BLOOD (2006)
Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia
P Johansson
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2006)
WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature
MA Elliott et al.
LEUKEMIA (2005)
Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia
C Terre et al.
LEUKEMIA (2004)
Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib
M Loriaux et al.
LEUKEMIA & LYMPHOMA (2004)
A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia
C Roche-Lestienne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Cytogenetic and molecular genetic evolution of chronic myeloid leukemia
B Johansson et al.
ACTA HAEMATOLOGICA (2002)
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
ME Gorre et al.
SCIENCE (2001)
分享论文
